Aurinia Pharmaceuticals Inc. (NASDAQ:AUPH) Holdings Raised by DNB Asset Management AS

DNB Asset Management AS grew its stake in shares of Aurinia Pharmaceuticals Inc. (NASDAQ:AUPHGet Rating) (TSE:AUP) by 4.1% in the 1st quarter, HoldingsChannel reports. The firm owned 243,433 shares of the biotechnology company’s stock after acquiring an additional 9,539 shares during the quarter. DNB Asset Management AS’s holdings in Aurinia Pharmaceuticals were worth $3,014,000 at the end of the most recent quarter.

Several other hedge funds and other institutional investors also recently made changes to their positions in the company. Pictet Asset Management SA lifted its holdings in shares of Aurinia Pharmaceuticals by 42.6% during the fourth quarter. Pictet Asset Management SA now owns 1,449,624 shares of the biotechnology company’s stock valued at $33,153,000 after purchasing an additional 433,205 shares during the last quarter. Citigroup Inc. lifted its holdings in shares of Aurinia Pharmaceuticals by 7,641.6% during the fourth quarter. Citigroup Inc. now owns 768,195 shares of the biotechnology company’s stock valued at $17,569,000 after purchasing an additional 758,272 shares during the last quarter. SG Americas Securities LLC raised its position in Aurinia Pharmaceuticals by 59.7% during the fourth quarter. SG Americas Securities LLC now owns 656,205 shares of the biotechnology company’s stock valued at $15,007,000 after buying an additional 245,417 shares during the period. Renaissance Technologies LLC acquired a new position in Aurinia Pharmaceuticals during the fourth quarter valued at $10,682,000. Finally, Liontrust Investment Partners LLP acquired a new position in Aurinia Pharmaceuticals during the fourth quarter valued at $10,211,000. 33.09% of the stock is owned by institutional investors and hedge funds.

Shares of NASDAQ AUPH opened at $11.54 on Friday. The firm has a market cap of $1.64 billion, a price-to-earnings ratio of -9.02 and a beta of 1.09. The business’s 50-day simple moving average is $11.08 and its 200-day simple moving average is $14.57. Aurinia Pharmaceuticals Inc. has a 52 week low of $8.86 and a 52 week high of $33.97.

Aurinia Pharmaceuticals (NASDAQ:AUPHGet Rating) (TSE:AUP) last issued its quarterly earnings data on Tuesday, May 10th. The biotechnology company reported ($0.27) EPS for the quarter, missing analysts’ consensus estimates of ($0.26) by ($0.01). The company had revenue of $21.63 million for the quarter, compared to analyst estimates of $19.68 million. Aurinia Pharmaceuticals had a negative net margin of 253.66% and a negative return on equity of 43.20%. During the same period in the prior year, the company posted ($0.40) EPS. As a group, analysts predict that Aurinia Pharmaceuticals Inc. will post -0.7 earnings per share for the current year.

AUPH has been the topic of several recent analyst reports. HC Wainwright dropped their price target on Aurinia Pharmaceuticals from $33.00 to $30.00 in a research report on Wednesday, May 4th. Royal Bank of Canada dropped their target price on Aurinia Pharmaceuticals from $27.00 to $22.00 and set an “outperform” rating on the stock in a research report on Thursday, April 28th. SVB Leerink dropped their target price on Aurinia Pharmaceuticals from $30.00 to $22.00 and set an “outperform” rating on the stock in a research report on Tuesday, March 8th. StockNews.com raised Aurinia Pharmaceuticals from a “sell” rating to a “hold” rating in a research report on Monday, May 23rd. Finally, Cantor Fitzgerald reaffirmed an “overweight” rating on shares of Aurinia Pharmaceuticals in a research report on Thursday, April 28th. Two analysts have rated the stock with a hold rating and six have issued a buy rating to the company’s stock. According to data from MarketBeat, Aurinia Pharmaceuticals currently has a consensus rating of “Moderate Buy” and a consensus price target of $25.60.

Aurinia Pharmaceuticals Company Profile (Get Rating)

Aurinia Pharmaceuticals Inc, a commercial-stage biopharmaceutical company, focuses on developing and commercializing therapies to treat various diseases with unmet medical need in the United States and internationally. The company offers LUPKYNIS for the treatment of adult patients with active lupus nephritis.

Recommended Stories

Want to see what other hedge funds are holding AUPH? Visit HoldingsChannel.com to get the latest 13F filings and insider trades for Aurinia Pharmaceuticals Inc. (NASDAQ:AUPHGet Rating) (TSE:AUP).

Institutional Ownership by Quarter for Aurinia Pharmaceuticals (NASDAQ:AUPH)

Receive News & Ratings for Aurinia Pharmaceuticals Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for Aurinia Pharmaceuticals and related companies with MarketBeat.com's FREE daily email newsletter.